Grünenthal has received Orphan Drug and Rare Pediatric Disease designations from the US Food and Drug Administration for ...

The UK’s ageing population is reshaping healthcare demand in largely predictable and preventable ways. Nearly one in five ...

Last year I engineered an advanced agentic AI pharma strategy development application. One year later, after many ...

Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

Option offers once‑daily semaglutide tablets for adults living with obesity A first‑of‑its‑kind daily GLP‑1 weight‑loss pill has launched in the UK, expanding treatment options for adults living with ...

Novartis has secured European Commission approval for Itvisma for the treatment of children aged two years and older, as well ...

Applications have opened for the ninth cohort of KQ Labs, the national accelerator for data‑driven health start‑ups delivered ...

AlzeCure Pharma has signed an out‑licensing and collaboration agreement with Danish biotech QuantumCell ApS, granting global ...

R1 Therapeutics has formed a scientific advisory board comprising seven internationally recognised nephrology experts as the ...

Racura Oncology has treated the first patient in its phase 1 HARNESS‑1 clinical trial of RC220 for EGFR‑mutant non‑small cell ...

First immunotherapy approved for LACC in England offers new treatment option for women MSD has welcomed the National Institute for Health and Care Excellence’s recommendation of pembrolizumab ...